Main Line pharma firm awarded patent for cannabidiol treatment
The U.S. Patent and Trademark Office has issued a patent to Zynerba Pharmaceuticals for the company ’s lead new drug candidate, a synthetic cannabidiol medicine.
The patent, which expires in 2038, expands the Devon company’s intellectual property portfolio covering the experimental therapy called Zygel, which is formulated as a gel that is applied to the skin.
Cannabidiol is a compound found in cannabis plants.
Zygel is in late-stage clinical testing as potential treatment for fragile X syndrome.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news